期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西格列汀治疗2型糖尿病的临床研究进展 被引量：24

在线阅读 下载PDF
导出
摘要 西格列汀是一种口服给药的二肽基肽酶-4抑制药。西格列汀单独用药可改善血糖,与二甲双胍、胰岛素、磺酰脲类、噻唑烷二酮类联合用药可增强疗效,并且不增加低血糖的风险,也不增加患者体质量。该文综述了西格列汀的药动学特点、单药治疗和联合治疗的国内外临床研究进展及安全性等。
作者 胡洁 安富荣
机构地区 上海交通大学医学院附属仁济医院药剂科
出处 《医药导报》 CAS 北大核心 2013年第6期760-764,共5页 Herald of Medicine
关键词 西格列汀 糖尿病 2型 二肽基肽酶-4抑制药
分类号 R977.15 [医药卫生—药品] R587.1 [医药卫生—内分泌]
作者简介 胡洁（1969-），女，上海人，主管药师，研究方向：临床药学。电话：021—53882069，E-mail：hujie2201@163．com 通讯作者安富荣（1963-），女，山东人，主任药师，硕士，研究方向：药物制剂及药动学。电话：021—53882129，E-mail：furongan@yahoo．com．cn。
  • 相关文献

参考文献28

  • 1DHILLON S. Sitagliptin : a review of its use in the mana-gement of type 2 diabetes mellitus [ J]. Drugs, 2010, 70(4) :489-512.
  • 2HERMAN G A, STEVENS C, VANDYCK K,et al. Phar-macokinetics and pharmacodynamics of sitagliptin,aninhibitor of dipeptidyl peptidase IV,in healthy subjects :results from two randomized,double-blind,placebo-controlled studies with single oral doses [ J]. ClinPharmacol Ther,2005,78(6) : 675-688.
  • 3BERGMAN A J, STEVENS C,ZHOU Y Y,et al. Phar-macokinetic and pharmacodynamic properties of multipleoral doses of sitagliptin, a dipeptidyl peptidase-IVinhibitor: a double-blind, randomized, placebo-controlledstudy in healthy male volunteers [ J] . Clin Ther,2006,28(1): 55-72.
  • 4MIGOYA E M, STEVENS C H, BERGMAN A J,et al.Effect of moderate hepatic insufficiency on thepharmacokinetics of sitagliptin [ J]. Can J Clin Pharmacol,2009,16(1): 165-170.
  • 5ASCHNER P, MICKEL C,KIPNES M S,et al. Effect of thedipeptidyl peptidase-4 inhibitor sitagliptin as monotherapyon glycemic control in patients with type 2 diabetes [ J].Diabetes Care,2006,29( 12) : 2632-2637.
  • 6RAZ I,HANEFELD M,XU L,et al. Efficacy and safety ofthe dipeptidyl peptidase-4 inhibitor sitagliptin asmonotherapy in patients with type 2 diabetes mellitus [ J].Diabetologia ,2006,49 (11) ; 2564-2571.
  • 7MOHAN V,YANG W,SON H Y,et al. Efficacy and safetyof sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea [ J]. Diabetes Res ClinPract,2009,83(l) : 106-116.
  • 8NONAKA K,KAKIKAWA T,SATO A,et al. Efficacy andsafety of sitagliptin monotherapy in Japanese patients withtype 2 diabetes [ J] . Diabetes Res Clin Pract,2008,79(2):291-298.
  • 9ASCHNER P,KATZEFF H L,GUO H,et al. Efficacy andsafety of monotherapy of sitagliptin compared withmetformin in patients with type 2 diabetes [ J] . DiabetesObes Metab,2010,12(3) : 252-261.
  • 10IWAMOTO Y,TAJIMA N,KADOWAKI T,et al. Efficacyand safety of sitagliptin monotherapy compared withvoglibose in Japanese patients with type 2 diabetes : arandomized,double-blind trial [ J]. Diabetes Obes Metab,2010,12(7) : 613-622.

二级参考文献28

  • 1李学忠.诺和灵N联合二甲双胍治疗继发性失效2型糖尿病53例[J].医学理论与实践,2006,19(8):932-932. 被引量：3
  • 2Non aka K, Kakikawa T, Sato A, et al. Efficacy and safety of s itag lipt in mon oth erapy in Jap an ese pat ients with type 2diabetes [ J]. Diabetes Res Clin Pract, 2008,79(2) :291-298.
  • 3Shimpil RD, Patill PH, Kuchake VG, et al. Comparison ofeffect of metformin in combination with glimepiride and glib enclamide on glycaemic control in patient with type 2 diabetes mellitus. International Journal of PharmTech Research [J]. In ternational Journal of Pharm Tech Research, 2009, 1 ( 1 ) : 50- 61.
  • 4Ahr6n B. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes [J]. Curt Diab Rep, 2011,11 (2) : 83-90.
  • 5Druker DJ, Nauck MA. The incretin system: glucagon-like pep- tide-I receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006,368 : 1696-17115;.
  • 6White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use[J]. Clin Diabetes, 201)8,26 : 53-57.
  • 7Mohan V,Yang W, Son HY,et a l. Efficacy and safety of sita gliptin in the treatment of patients with type 2 diabetes in Chi na, India, and korea[J]. Diabetes Res ClinPract, 20119,83 ( 1 ) 1116-116.
  • 8Mori Y, Taniguchi Y, Matsuura K, et al. Effects of sitaglip tin on 24 h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring[J]. DI abetes Technol Ther,2011,13(7):699-71)3.
  • 9Debora Williams-Herman, Elizabeth Round, Arlene S Swern, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes:a pooled analysis[J]. BMC Endocrine Disorders, 2(11)8, 8:14.
  • 10Williams-Herman D, Johnson J, Teng R,et al. Efficacy and safety of Sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2010,12(5) : 442-451.

共引文献83

同被引文献146

引证文献24

二级引证文献88

医药导报
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部